Azizi Miskon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Azizi Miskon has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Siti Nooraya Mohd Tawil
Department of Electrical and Electronics Engineering, Universiti Pertahanan Nasional Malaysia, Sungai Besi, Kuala Lumpur, Malaysia
11 shared publications - Ahmad Mujahid Ahmad Zaidi
Faculty of Engineering, National Defence University of Malaysia, Kuala Lumpur, Malaysia
8 shared publications - Yan Yik Lim
Faculty of Defence Science and Technology, National Defence University of Malaysia, Sungai Besi Prime Camp, Kuala Lumpur 57000, Malaysia
8 shared publications Hiroshi Uyama
Osaka University
4 shared publications- Muhamad Abu Bakar
Faculty of Medicine and Defence Health, National Defence University of Malaysia, Prime Camp, Sungai Besi, Kuala Lumpur 57000, Malaysia
4 shared publications Atsushi Mahara
Department of Biomedical Engineering, National Cerebral and Cardiovascular Center Research Institute, 5-7-1 Fujishirodai, Suita, Osaka, 565-8565, Japan
3 shared publications
Latest Publications
- Open Access
- 1 February 2026
- Published by Institute of Advanced Engineering and Science in Indonesian Journal of Electrical Engineering and Computer Science
- Vol. 41 (2)
Hybrid SVM–ANN system for automated MRI diagnosis of anterior cruciate ligament injuries
Anterior cruciate ligament (ACL) tears are a frequent cause of knee instability, yet magnetic resonance imaging (MRI) interpretation remains time-consuming and observer-dependent. This paper presents an automated MRI framework for ACL injury screening and severity grading using a hybrid support vector machine–artificial neural network (SVM–ANN) model. A balanced dataset of 600 sagittal knee MRI images from Hospital Taiping (normal, partial tear, complete tear) was standardized via resizing, region-of-interest cropping, contrast enhancement, noise filtering, and segmentation. Morphological and texture features were extracted and reduced using principal component analysis (PCA). The SVM performs the initial screening (injured vs. non-injured) and samples predicted as injured are passed to the artificial neural network (ANN) to classify severity. Using confusion-matrix and receiver operating characteristic (ROC) evaluation, the proposed system achieved 86.2% overall accuracy and 81.7% sensitivity, with the ANN reaching approximately 95% accuracy on injured cases forwarded for grading. A clinician usability survey indicated high acceptance (~95%), supporting the feasibility of deployment as a lightweight decision-support tool. Limitations include reliance on single sagittal slices and single-sequence data; future work will incorporate multi-slice/3D and multi-sequence MRI to improve sensitivity and generalizability.
- 1 February 2026
- Published by Institute of Advanced Engineering and Science in Indonesian Journal of Electrical Engineering and Computer Science
- Vol. 41 (2)
Open AccessHybrid SVM–ANN system for automated MRI diagnosis of anterior cruciate ligament injuries
Anterior cruciate ligament (ACL) tears are a frequent cause of knee instability, yet magnetic resonance imaging (MRI) interpretation remains time-consuming and observer-dependent. This paper presents an automated MRI framework for ACL injury screening and severity grading using a hybrid support vector machine–artificial neural network (SVM–ANN) model. A balanced dataset of 600 sagittal knee MRI images from Hospital Taiping (normal, partial tear, complete tear) was standardized via resizing, region-of-interest cropping, contrast enhancement, noise filtering, and segmentation. Morphological and texture features were extracted and reduced using principal component analysis (PCA). The SVM performs the initial screening (injured vs. non-injured) and samples predicted as injured are passed to the artificial neural network (ANN) to classify severity. Using confusion-matrix and receiver operating characteristic (ROC) evaluation, the proposed system achieved 86.2% overall accuracy and 81.7% sensitivity, with the ANN reaching approximately 95% accuracy on injured cases forwarded for grading. A clinician usability survey indicated high acceptance (~95%), supporting the feasibility of deployment as a lightweight decision-support tool. Limitations include reliance on single sagittal slices and single-sequence data; future work will incorporate multi-slice/3D and multi-sequence MRI to improve sensitivity and generalizability.
- Open Access
- 21 December 2025
- Published by Association for Computing Machinery (ACM)
- p. 227-233
Comparative Analysis of EEG Signals for Controlling a Prosthetic Hand: Audio vs. Visual Instruction Methods
- 21 December 2025
- Published by Association for Computing Machinery (ACM)
- p. 227-233
Open AccessComparative Analysis of EEG Signals for Controlling a Prosthetic Hand: Audio vs. Visual Instruction Methods
- 18 April 2024
- Published by Springer Nature
- p. 115-123
Nanomaterial in Robotics: Bridging the Gap Between Current Applications and Future Possibilities
- 18 April 2024
- Published by Springer Nature
- p. 115-123
Nanomaterial in Robotics: Bridging the Gap Between Current Applications and Future Possibilities
- Open Access
Combining Copper and Zinc into a Biosensor for Anti-Chemoresistance and Achieving Osteosarcoma Therapeutic Efficacy
Due to its built-up chemoresistance after prolonged usage, the demand for replacing platinum in metal-based drugs (MBD) is rising. The first MBD approved by the FDA for cancer therapy was cisplatin in 1978. Even after nearly four and a half decades of trials, there has been no significant improvement in osteosarcoma (OS) therapy. In fact, many MBD have been developed, but the chemoresistance problem raised by platinum remains unresolved. This motivates us to elucidate the possibilities of the copper and zinc (CuZn) combination to replace platinum in MBD. Thus, the anti-chemoresistance properties of CuZn and their physiological functions for OS therapy are highlighted. Herein, we summarise their chelators, main organic solvents, and ligand functions in their structures that are involved in anti-chemoresistance properties. Through this review, it is rational to discuss their ligands’ roles as biosensors in drug delivery systems. Hereafter, an in-depth understanding of their redox and photoactive function relationships is provided. The disadvantage is that the other functions of biosensors cannot be elaborated on here. As a result, this review is being developed, which is expected to intensify OS drugs with higher cure rates. Nonetheless, this advancement intends to solve the major chemoresistance obstacle towards clinical efficacy.
Open AccessCombining Copper and Zinc into a Biosensor for Anti-Chemoresistance and Achieving Osteosarcoma Therapeutic Efficacy
Due to its built-up chemoresistance after prolonged usage, the demand for replacing platinum in metal-based drugs (MBD) is rising. The first MBD approved by the FDA for cancer therapy was cisplatin in 1978. Even after nearly four and a half decades of trials, there has been no significant improvement in osteosarcoma (OS) therapy. In fact, many MBD have been developed, but the chemoresistance problem raised by platinum remains unresolved. This motivates us to elucidate the possibilities of the copper and zinc (CuZn) combination to replace platinum in MBD. Thus, the anti-chemoresistance properties of CuZn and their physiological functions for OS therapy are highlighted. Herein, we summarise their chelators, main organic solvents, and ligand functions in their structures that are involved in anti-chemoresistance properties. Through this review, it is rational to discuss their ligands’ roles as biosensors in drug delivery systems. Hereafter, an in-depth understanding of their redox and photoactive function relationships is provided. The disadvantage is that the other functions of biosensors cannot be elaborated on here. As a result, this review is being developed, which is expected to intensify OS drugs with higher cure rates. Nonetheless, this advancement intends to solve the major chemoresistance obstacle towards clinical efficacy.
- Open Access
- 28 February 2023
- Published by MDPI AG in Preprints.org
Combining Copper and Zinc into a Biosensor for Anti-Chemoresistance and Achieving Osteosarcoma Therapeutic Efficacy
Due to its built-up chemoresistance after prolonged usage, the demand for replacing platinum in metal-based drugs (MBD) is rising. The first MBD approved by the FDA for cancer therapy was cisplatin in 1978. Even after nearly four and a half decades of trials, there has been no significant improvement in osteosarcoma (OS) therapy. In fact, many MBD have been developed, but the chemoresistance problem raised by platinum remains unresolved. This motivates us to elucidate the possibilities of the copper and zinc (CuZn) combination to replace platinum in MBD. Thus, the anti-chemoresistance properties of CuZn and their physiological functions for OS therapy are highlighted. Herein, we summarise their chelators, main organic solvents, and ligand functions in their structures that are involved in anti-chemoresistance properties. Through this review, it is rational to discuss their ligands’ roles as biosensors in drug delivery systems. Hereafter, an in-depth understanding of their redox and photoactive function relationships is provided. The disadvantage is that the other functions of biosensors cannot be elaborated on here. As a result, this review is being developed, which is expected to intensify OS drugs with higher cure rates. Nonetheless, this advancement intends to solve the major chemoresistance obstacle towards clinical efficacy.
- 28 February 2023
- Published by MDPI AG in Preprints.org
Open AccessCombining Copper and Zinc into a Biosensor for Anti-Chemoresistance and Achieving Osteosarcoma Therapeutic Efficacy
Due to its built-up chemoresistance after prolonged usage, the demand for replacing platinum in metal-based drugs (MBD) is rising. The first MBD approved by the FDA for cancer therapy was cisplatin in 1978. Even after nearly four and a half decades of trials, there has been no significant improvement in osteosarcoma (OS) therapy. In fact, many MBD have been developed, but the chemoresistance problem raised by platinum remains unresolved. This motivates us to elucidate the possibilities of the copper and zinc (CuZn) combination to replace platinum in MBD. Thus, the anti-chemoresistance properties of CuZn and their physiological functions for OS therapy are highlighted. Herein, we summarise their chelators, main organic solvents, and ligand functions in their structures that are involved in anti-chemoresistance properties. Through this review, it is rational to discuss their ligands’ roles as biosensors in drug delivery systems. Hereafter, an in-depth understanding of their redox and photoactive function relationships is provided. The disadvantage is that the other functions of biosensors cannot be elaborated on here. As a result, this review is being developed, which is expected to intensify OS drugs with higher cure rates. Nonetheless, this advancement intends to solve the major chemoresistance obstacle towards clinical efficacy.
- Open Access
- 7 February 2023
- Published by MDPI AG in Preprints.org
Relationship between Osteosarcoma Therapy and Tumorigenesis, Metastasis, Immune Evasion, and Chemoresistance
There has been no significant efficacy in treatment for osteosarcoma (OS) metastasis after nearly four decades of trials. This motivates us to elucidate OS therapies according to their four bidirectional mutation stages. To refresh the OS therapy status quo, the historical developments and clinical advancements are briefly described. However, the main issue of metastasis remains unresolved, accounting for 90% of pulmonary metastasis deaths. Thus, this metastasis problem is related to immune evasion and chemoresistance that are being induced after long-term treatment by the use of immunotherapy for tumorigenesis. Therefore, it is rationale to discuss the relationship cycles of mutation stages including tumorigenesis, metastasis, immune evasion, and chemoresistance. Even though many combinational and targeted therapies have been developed to intensify these mutation treatments, successful clinical translations with higher cure rates are still rare. Through this review, an in-depth understanding of the bidirectional relationship between the four OS mutation stages and their respective therapies is provided. Herein, we summarise the medicines used to treat tumorigenesis, including COLGALT2 inhibitors, Tra2B, and AGAP1, miR-148a and miR-21-5p EVs, and the lncRNA LIFR-AS1. Following the medicines used to treat metastasis are AXL, miR-135a-5p, mRNA BCL6, TGFβ1, Tim-3, SOCS5, CASC15, KLF3-AS1, PDCD4, ATG5, and Rab22a-NeoF1. Then the medicines used to treat immune evasion are N-cadherin, anti-IL-9, USP12 inhibitor, IgG-4+ B-cells, LAP inhibitor, anti-Wnt2 mAb, anti-αvβ8 integrin, HK2-mediated IκBα, IDO inhibitor with NO, and TGF-βRII with anti-IgG1. Finally, the medicines used to treat chemoresistance are DHFR, FPGS, HSP-90AA1, XCT-790, ATKI, and IGF1. As a result, this contribution is expected to serve as a reference and guide for scientists and clinicians.
- 7 February 2023
- Published by MDPI AG in Preprints.org
Open AccessRelationship between Osteosarcoma Therapy and Tumorigenesis, Metastasis, Immune Evasion, and Chemoresistance
There has been no significant efficacy in treatment for osteosarcoma (OS) metastasis after nearly four decades of trials. This motivates us to elucidate OS therapies according to their four bidirectional mutation stages. To refresh the OS therapy status quo, the historical developments and clinical advancements are briefly described. However, the main issue of metastasis remains unresolved, accounting for 90% of pulmonary metastasis deaths. Thus, this metastasis problem is related to immune evasion and chemoresistance that are being induced after long-term treatment by the use of immunotherapy for tumorigenesis. Therefore, it is rationale to discuss the relationship cycles of mutation stages including tumorigenesis, metastasis, immune evasion, and chemoresistance. Even though many combinational and targeted therapies have been developed to intensify these mutation treatments, successful clinical translations with higher cure rates are still rare. Through this review, an in-depth understanding of the bidirectional relationship between the four OS mutation stages and their respective therapies is provided. Herein, we summarise the medicines used to treat tumorigenesis, including COLGALT2 inhibitors, Tra2B, and AGAP1, miR-148a and miR-21-5p EVs, and the lncRNA LIFR-AS1. Following the medicines used to treat metastasis are AXL, miR-135a-5p, mRNA BCL6, TGFβ1, Tim-3, SOCS5, CASC15, KLF3-AS1, PDCD4, ATG5, and Rab22a-NeoF1. Then the medicines used to treat immune evasion are N-cadherin, anti-IL-9, USP12 inhibitor, IgG-4+ B-cells, LAP inhibitor, anti-Wnt2 mAb, anti-αvβ8 integrin, HK2-mediated IκBα, IDO inhibitor with NO, and TGF-βRII with anti-IgG1. Finally, the medicines used to treat chemoresistance are DHFR, FPGS, HSP-90AA1, XCT-790, ATKI, and IGF1. As a result, this contribution is expected to serve as a reference and guide for scientists and clinicians.
- Open Access
CuZn Complex Used in Electrical Biosensors for Drug Delivery Systems
This paper is to discuss the potential of using CuZn in an electrical biosensor drug carrier for drug delivery systems. CuZn is the main semiconductor ingredient that has great promise as an electrochemical detector to trigger releases of active pharmaceutical ingredients (API). This CuZn biosensor is produced with a green metal of frameworks, which is an anion node in conductive polymers linked by bioactive ligands using metal–polymerisation technology. The studies of Cu, Zn, and their oxides are highlighted by their electrochemical performance as electrical biosensors to electrically trigger API. The three main problems, which are glucose oxidisation, binding affinity, and toxicity, are highlighted, and their solutions are given. Moreover, their biocompatibilities, therapeutic efficacies, and drug delivery efficiencies are discussed with details given. Our three previous investigations of CuZn found results similar to those of other authors’ in terms of multiphases, polymerisation, and structure. This affirms that our research is on the right track, especially that related to green synthesis using plant extract, CuZn as a nanochip electric biosensor, and bioactive ligands to bind API, which are limited to the innermost circle of the non-enzymatic glucose sensor category.
Open AccessCuZn Complex Used in Electrical Biosensors for Drug Delivery Systems
This paper is to discuss the potential of using CuZn in an electrical biosensor drug carrier for drug delivery systems. CuZn is the main semiconductor ingredient that has great promise as an electrochemical detector to trigger releases of active pharmaceutical ingredients (API). This CuZn biosensor is produced with a green metal of frameworks, which is an anion node in conductive polymers linked by bioactive ligands using metal–polymerisation technology. The studies of Cu, Zn, and their oxides are highlighted by their electrochemical performance as electrical biosensors to electrically trigger API. The three main problems, which are glucose oxidisation, binding affinity, and toxicity, are highlighted, and their solutions are given. Moreover, their biocompatibilities, therapeutic efficacies, and drug delivery efficiencies are discussed with details given. Our three previous investigations of CuZn found results similar to those of other authors’ in terms of multiphases, polymerisation, and structure. This affirms that our research is on the right track, especially that related to green synthesis using plant extract, CuZn as a nanochip electric biosensor, and bioactive ligands to bind API, which are limited to the innermost circle of the non-enzymatic glucose sensor category.
- Open Access
- 27 October 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (11) , 1330
Composing On-Program Triggers and On-Demand Stimuli into Biosensor Drug Carriers in Drug Delivery Systems for Programmable Arthritis Therapy
Medication in arthritis therapies is complex because the inflammatory progression of rheumatoid arthritis (RA) and osteoarthritis (OA) is intertwined and influenced by one another. To address this problem, drug delivery systems (DDS) are composed of four independent exogenous triggers and four dependent endogenous stimuli that are controlled on program and induced on demand, respectively. However, the relationships between the mechanisms of endogenous stimuli and exogenous triggers with pathological alterations remain unclear, which results in a major obstacle in terms of clinical translation. Thus, the rationale for designing a guidance system for these mechanisms via their key irritant biosensors is in high demand. Many approaches have been applied, although successful clinical translations are still rare. Through this review, the status quo in historical development is highlighted in order to discuss the unsolved clinical difficulties such as infiltration, efficacy, drug clearance, and target localisation. Herein, we summarise and discuss the rational compositions of exogenous triggers and endogenous stimuli for programmable therapy. This advanced active pharmaceutical ingredient (API) implanted dose allows for several releases by remote controls for endogenous stimuli during lesion infections. This solves the multiple implantation and local toxic accumulation problems by using these flexible desired releases at the specified sites for arthritis therapies.
- 27 October 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (11) , 1330
Open AccessComposing On-Program Triggers and On-Demand Stimuli into Biosensor Drug Carriers in Drug Delivery Systems for Programmable Arthritis Therapy
Medication in arthritis therapies is complex because the inflammatory progression of rheumatoid arthritis (RA) and osteoarthritis (OA) is intertwined and influenced by one another. To address this problem, drug delivery systems (DDS) are composed of four independent exogenous triggers and four dependent endogenous stimuli that are controlled on program and induced on demand, respectively. However, the relationships between the mechanisms of endogenous stimuli and exogenous triggers with pathological alterations remain unclear, which results in a major obstacle in terms of clinical translation. Thus, the rationale for designing a guidance system for these mechanisms via their key irritant biosensors is in high demand. Many approaches have been applied, although successful clinical translations are still rare. Through this review, the status quo in historical development is highlighted in order to discuss the unsolved clinical difficulties such as infiltration, efficacy, drug clearance, and target localisation. Herein, we summarise and discuss the rational compositions of exogenous triggers and endogenous stimuli for programmable therapy. This advanced active pharmaceutical ingredient (API) implanted dose allows for several releases by remote controls for endogenous stimuli during lesion infections. This solves the multiple implantation and local toxic accumulation problems by using these flexible desired releases at the specified sites for arthritis therapies.
- Open Access
Multifunction Web-like Polymeric Network Bacterial Cellulose Derived from SCOBY as Both Electrodes and Electrolytes for Pliable and Low-Cost Supercapacitor
In this work, bacterial cellulose (BC)-based polymer derived from a symbiotic culture of bacteria and yeast (SCOBY) are optimized as both electrodes and electrolytes to fabricate a flexible and free-standing supercapacitor. BC is a multifunction and versatile polymer. Montmorillonite (MMT) and sodium bromide (NaBr) are used to improve mechanical strength and as the ionic source, respectively. From XRD analysis, it is found that the addition of MMT and NaBr has reduced the crystallinity of the electrolyte. Most interaction within the electrolyte happens in the region of the OH band, as verified using FTIR analysis. A maximum room temperature conductivity of (1.09 ± 0.02) × 10−3 S/cm is achieved with 30 wt.% NaBr. The highest conducting SCOBY-based electrolytes have a decompose voltage and ionic transference number of 1.48 V and 0.97, respectively. The multiwalled carbon nanotube is employed as the active material held by the fibrous network of BC. Cyclic voltammetry shows a rectangular shape CV plot with the absence of a redox peak. The supercapacitor is charged and discharged in a zig-zag-shaped Perspex plate for 1000 cycles with a decent performance.
Open AccessMultifunction Web-like Polymeric Network Bacterial Cellulose Derived from SCOBY as Both Electrodes and Electrolytes for Pliable and Low-Cost Supercapacitor
In this work, bacterial cellulose (BC)-based polymer derived from a symbiotic culture of bacteria and yeast (SCOBY) are optimized as both electrodes and electrolytes to fabricate a flexible and free-standing supercapacitor. BC is a multifunction and versatile polymer. Montmorillonite (MMT) and sodium bromide (NaBr) are used to improve mechanical strength and as the ionic source, respectively. From XRD analysis, it is found that the addition of MMT and NaBr has reduced the crystallinity of the electrolyte. Most interaction within the electrolyte happens in the region of the OH band, as verified using FTIR analysis. A maximum room temperature conductivity of (1.09 ± 0.02) × 10−3 S/cm is achieved with 30 wt.% NaBr. The highest conducting SCOBY-based electrolytes have a decompose voltage and ionic transference number of 1.48 V and 0.97, respectively. The multiwalled carbon nanotube is employed as the active material held by the fibrous network of BC. Cyclic voltammetry shows a rectangular shape CV plot with the absence of a redox peak. The supercapacitor is charged and discharged in a zig-zag-shaped Perspex plate for 1000 cycles with a decent performance.
- Open Access
Structural Strength Analyses for Low Brass Filler Biomaterial with Anti-Trauma Effects in Articular Cartilage Scaffold Design
The existing harder biomaterial does not protect the tissue cells with blunt-force trauma effects, making it a poor choice for the articular cartilage scaffold design. Despite the traditional mechanical strengths, this study aims to discover alternative structural strengths for the scaffold supports. The metallic filler polymer reinforced method was used to fabricate the test specimen, either low brass (Cu80Zn20) or titanium dioxide filler, with composition weight percentages (wt.%) of 0, 2, 5, 15, and 30 in polyester urethane adhesive. The specimens were investigated for tensile, flexural, field emission scanning electron microscopy (FESEM), and X-ray diffraction (XRD) tests. The tensile and flexural test results increased with wt.%, but there were higher values for low brass filler specimens. The tensile strength curves were extended to discover an additional tensile strength occurring before 83% wt.%. The higher flexural stress was because of the Cu solvent and Zn solute substituting each other randomly. The FESEM micrograph showed a cubo-octahedron shaped structure that was similar to the AuCu3 structure class. The XRD pattern showed two prominent peaks of 2θ of 42.6° (110) and 49.7° (200) with d-spacings of 1.138 Å and 1.010 Å, respectively, that indicated the typical face-centred cubic superlattice structure with Cu and Zn atoms. Compared to the copper, zinc, and cart brass, the low brass indicated these superlattice structures had ordered–disordered transitional states. As a result, this additional strength was created by the superlattice structure and ordered–disordered transitional states. This innovative strength has the potential to develop into an anti-trauma biomaterial for osteoarthritic patients.
Open AccessStructural Strength Analyses for Low Brass Filler Biomaterial with Anti-Trauma Effects in Articular Cartilage Scaffold Design
The existing harder biomaterial does not protect the tissue cells with blunt-force trauma effects, making it a poor choice for the articular cartilage scaffold design. Despite the traditional mechanical strengths, this study aims to discover alternative structural strengths for the scaffold supports. The metallic filler polymer reinforced method was used to fabricate the test specimen, either low brass (Cu80Zn20) or titanium dioxide filler, with composition weight percentages (wt.%) of 0, 2, 5, 15, and 30 in polyester urethane adhesive. The specimens were investigated for tensile, flexural, field emission scanning electron microscopy (FESEM), and X-ray diffraction (XRD) tests. The tensile and flexural test results increased with wt.%, but there were higher values for low brass filler specimens. The tensile strength curves were extended to discover an additional tensile strength occurring before 83% wt.%. The higher flexural stress was because of the Cu solvent and Zn solute substituting each other randomly. The FESEM micrograph showed a cubo-octahedron shaped structure that was similar to the AuCu3 structure class. The XRD pattern showed two prominent peaks of 2θ of 42.6° (110) and 49.7° (200) with d-spacings of 1.138 Å and 1.010 Å, respectively, that indicated the typical face-centred cubic superlattice structure with Cu and Zn atoms. Compared to the copper, zinc, and cart brass, the low brass indicated these superlattice structures had ordered–disordered transitional states. As a result, this additional strength was created by the superlattice structure and ordered–disordered transitional states. This innovative strength has the potential to develop into an anti-trauma biomaterial for osteoarthritic patients.